2023 World Conference on Lung Cancer (Posters)-EP02.04. A Nanoplatform Based on an in Situ Tumor Vaccine and Activation of STING and TLR7/8 Pathways for Enhanced NSCLC Immunotherapy

EP02.04. A Nanoplatform Based on an in Situ Tumor Vaccine and Activation of STING and TLR7/8 Pathways for Enhanced NSCLC Immunotherapy - PDF(Slides)

Back to course

Pdf Summary

Researchers from South China University of Technology and Guangdong Provincial People's Hospital have developed a nanoplatform for enhanced immunotherapy in non-small cell lung cancer (NSCLC). The study, presented at the IASLC 2023 World Conference on Lung Cancer, focuses on the use of in situ tumor vaccines and the activation of STING and TLR7/8 pathways to improve the efficacy of immunotherapy.<br /><br />Immunotherapy has emerged as a promising treatment option for tumors. Therapeutic tumor vaccines, which induce T cell-mediated immune responses, have shown potential in destroying tumors and inhibiting recurrence and metastasis. However, the heterogeneity of tumors limits their effectiveness.<br /><br />In this study, the researchers developed a multifunctional nanopolymer called PEG-Ce6@PAEMA/R848. This nanopolymer consists of a photosensitizer, a tumor pH-sensitive polymer, and an immune adjuvant. The physicochemical properties and cytotoxicity of the nanopolymer were validated at the particle and cellular level.<br /><br />The researchers found that administration of PEG-Ce6@PAEMA/R848 at pH 6.5 resulted in the highest expression of CD86, a cell surface marker for dendritic cell (DC) maturation. They also observed that the nanopolymer effectively suppressed tumor growth in a mouse model.<br /><br />Furthermore, the study demonstrated that PEG-Ce6@PAEMA/R848 treatment led to increased infiltration of CD3/CD8 T cells, indicating an enhanced anti-tumor immune response. The nanopolymer was also found to induce immunogenic cell death and a systemic anti-tumor immune response.<br /><br />The researchers concluded that their strategy based on in situ tumor vaccine effects could effectively inhibit tumor growth and induce an anti-tumor immune response. They also expressed intentions to further investigate the therapeutic effect of the nanopolymer on metastatic and distal tumors.<br /><br />This work was supported by the Natural Science Foundation of Guangdong, the International Science and Technology Cooperation Program of Guangdong, and the Science and Technology Program of Guangzhou.<br /><br />In summary, this study presents a novel nanoplatform that shows promise for enhanced immunotherapy in NSCLC by utilizing in situ tumor vaccines and the activation of specific pathways. The research findings suggest that this strategy has the potential to improve tumor treatment outcomes and warrant further investigation.

Asset Subtitle

Haiyu Zhou

Meta Tag

Speaker Haiyu Zhou

Topic Tumor Biology: Preclinical Biology - Tumor Immunity

Keywords

nanoplatform

immunotherapy

non-small cell lung cancer

NSCLC

in situ tumor vaccines

STING pathway

TLR7/8 pathway

therapeutic tumor vaccines

multifunctional nanopolymer

PEG-Ce6@PAEMA/R848